Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective multicenter cohort study assessing the impact of patient age and comorbidities on safety and effectiveness outcomes in patients of Inflammatory Bowel Disease treated with Vedolizumab and Ustekinumab

X
Trial Profile

A prospective multicenter cohort study assessing the impact of patient age and comorbidities on safety and effectiveness outcomes in patients of Inflammatory Bowel Disease treated with Vedolizumab and Ustekinumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2021 Results of systematic review and meta-analysis of four studies assessed to compare maternal and fetal adverse outcomes in pregnancies of women with inflammatory bowel disease exposed to vedolizumab versus those on other treatment, published in the Journal of Gastroenterology and Hepatology.
    • 14 Sep 2020 New trial record
    • 09 Sep 2020 Results published in the Alimentary Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top